Scribe, Jennifer Doudna's newest startup, nabs a mega-round and a vocal investor
Nearly a decade ago, when the first CRISPR companies started looking for capital, Behzad Aghazadeh passed.
Aghazadeh, one of biotech’s more opinionated investors, had invested in gene editing before, but he had reservations about these companies: How would they navigate the patent jungle that cropped up around CRISPR-Cas9? How readily could they actually turn this bacterial-derived system into a human therapy? He maintains those concerns, even with those companies now worth over $1 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.